I guess now that June has passed, this is due an u
Post# of 148190
(Total Views: 380)
Posted On: 06/29/2019 8:01:29 PM
I guess now that June has passed, this is due an update. It has been a very busy first half of 2019, some of these milestone (several of the unsurprising ones we had listed). Q3 seems to have a lot of potential big milestones, finishing the BLA being the biggest.
Rolling BLA Review Approved for Combo
BLA Part 1 Submitted
TNBC FTD Approval
CMO deal with Samsung
Mono Investigatory Trial Enrollment Finished with goal met
Mono: IncellDx Dose/CCR5 Analysis Results
Mono Pivotal P3 Trial IND Submission
AACR Presentitions (Her2 with CCR5 connection and TNBC preclinical data)
Prostate Cancer Test 510(k) filing initiated
PReP Study with Thai Red Cross Announced
ASM Oral and Poster Presentations
Leronimab TNBC Pre-Clinical Data with 98% Mesastic Burden reduction
Added Dr. Brendan Rae and George Bitar
Started preclinical studies with other cancers and nash
Rolling BLA Review Approved for Combo
BLA Part 1 Submitted
TNBC FTD Approval
CMO deal with Samsung
Mono Investigatory Trial Enrollment Finished with goal met
Mono: IncellDx Dose/CCR5 Analysis Results
Mono Pivotal P3 Trial IND Submission
AACR Presentitions (Her2 with CCR5 connection and TNBC preclinical data)
Prostate Cancer Test 510(k) filing initiated
PReP Study with Thai Red Cross Announced
ASM Oral and Poster Presentations
Leronimab TNBC Pre-Clinical Data with 98% Mesastic Burden reduction
Added Dr. Brendan Rae and George Bitar
Started preclinical studies with other cancers and nash
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼